Comparative Effectiveness of Moderna, Pfizer-BioNTec

Immunocompromising Conditions â€” United States, M

Morbidity and Mortality Weekly Report
70, 1337-1343
DOI: 10.15585/mmwr.mm7038e1

Citation Report

#	Article	IF	Citations
2	Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison â€" Texas, Julyâ€"August 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1349-1354.	9.0	50
3	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance, 2021, 26, .	3.9	48
5	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
6	The impact and effectiveness of new coronavirus vaccine on disease outcome worldwide. Iberoamerican Journal of Medicine, 2021, 3, 332-340.	0.1	0
13	Boosters appear effective, but are they always needed?. Lancet, The, 2021, 398, 2055-2057.	6.3	3
15	Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19â€"Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity â€" Nine States, Januaryâ€"September 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1539-1544.	9.0	88
17	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science, 2022, 375, 331-336.	6.0	202
18	Targeting COVID Vaccine Hesitancy in Rural Communities in Tennessee: Implications for Extending the COVID-19 Pandemic in the South. Vaccines, 2021, 9, 1279.	2.1	37
19	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	3.8	458
21	Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. American Journal of Gastroenterology, 2022, 117, 176-179.	0.2	36
24	Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations. The Lancet Regional Health Americas, 2022, 5, 100133.	1.5	11
26	Is vaccination necessary for COVID-19 patients? A retrospective cohort study investigating reinfection rates and symptomatology in a tertiary hospital. Expert Review of Vaccines, 2022, 21, 249-252.	2.0	6
27	Predictors for Actual COVID-19 Vaccine Uptake and Intended Booster Dosage among Medical Students of an Osteopathic Medical School in New York. Epidemiologia, 2021, 2, 553-563.	1.1	12
33	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.4	30
34	How to Maintain Safety and Maximize the Efficacy of Cardiopulmonary Resuscitation in COVID-19 Patients: Insights from the Recent Guidelines. Journal of Clinical Medicine, 2021, 10, 5667.	1.0	3
36	SARS-CoV-2 booster vaccination for participants in â€œHIV cureâ€•related clinical trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, e30.	0.9	1
37	Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. New England Journal of Medicine, 2022, 386, 105-115.	13.9	182
38	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074.	2.8	22

#	Article	IF	Citations
40	Reasons in favour of universal vaccination campaign against COVID-19 in the pediatric population. Italian Journal of Pediatrics, 2022, 48, 4.	1.0	14
41	Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabolism Open, 2022, 13, 100159.	1.4	30
42	Adenovirus-based vaccinesâ€"a platform for pandemic preparedness against emerging viral pathogens. Molecular Therapy, 2022, 30, 1822-1849.	3.7	24
43	Dealing with a Pandemic: Emerging Tools, Solutions, and Challenges. Health Security, 2022, 20, 109-115.	0.9	2
44	Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women. Vaccines, 2022, 10, 101.	2.1	23
45	Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA - Journal of the American Medical Association, 2022, 327, 678.	3.8	53
46	VariaciÃ³n longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 45-50.	0.1	0
48	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. New England Journal of Medicine, 2022, 386, 933-941.	13.9	238
49	COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis â€" California and New York, Mayâ€"November 2021. Morbidity and Mortality Weekly Report, 2022, 71, 125-131.	9.0	119
50	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
51	COVID-19 Vaccines. Infectious Disease Clinics of North America, 2022, 36, 481-494.	1.9	13
52	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	3.8	76
55	Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged â‰¥65 years: a phase 2, randomised, open-label study. Lancet Respiratory Medicine,the, 2022, 10, 392-402.	5.2	60
56	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clinical Infectious Diseases, 2022, 75, e630-e644.	2.9	65
57	Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood, 2022, 139, 1903-1907.	0.6	30
58	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet, The, 2022, 399, 814-823.	6.3	196
60	SARS-CoV-2 Variants and Vaccination. Zoonoses, 2022, 2, .	0.5	16
63	Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2022, 20, 1881-1883.e1.	2.4	26

#	Article	IF	Citations
64	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Reviews Immunology, 2022, 22, 57-65.	10.6	217
65	BNT162b2 Vaccine Booster and Mortality Due to Covid-19. New England Journal of Medicine, 2021, 385, 2413-2420.	13.9	288
66	Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clinical Infectious Diseases, 2022, 75, e827-e837.	2.9	9
67	Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. Journal of Infectious Diseases, 2022, 225, 1694-1700.	1.9	14
69	Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans â€" Five Veterans Affairs Medical Centers, United States, February 1â€"September 30, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1700-1705.	9.0	73
70	Primary Care Concerns for the Aging Population With HIV. Topics in Antiviral Medicine, 2021, 29, 412-415.	0.1	0
71	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
72	Vaccination provides protection from respiratory deterioration and death among hospitalized COVIDâ€19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology, 2022, 94, 2849-2854.	2.5	19
74	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in Immunology, 2022, 13, 828053.	2.2	11
75	Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respiratory Medicine,the, 2022, 10, 557-565.	5.2	44
77	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Frontiers of Medicine, 2022, 16, 185-195.	1.5	11
78	The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data. Vaccines, 2022, 10, 320.	2.1	19
79	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. The Lancet Regional Health Americas, 2022, 9, 100198.	1.5	62
80	COVID-19: vaccines, efficacy and effects on variants. Current Opinion in Pulmonary Medicine, 2022, 28, 180-191.	1.2	24
82	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Frontiers in Microbiology, 2022, 13, 828806.	1.5	17
84	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. Archives of Pathology and Laboratory Medicine, 2022, 146, 677-685.	1.2	7
85	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2. Vaccines, 2022, 10, 322.	2.1	8
86	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. Lancet Respiratory Medicine,the, 2022, 10, 566-572.	5.2	23

#	Article	IF	Citations
88	Management Principles for the Cardiac Catheterization Laboratory During the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic. Interventional Cardiology Clinics, 2022, 11, 325-338.	0.2	1
89	Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. JAMA Network Open, 2022, 5, e225018.	2.8	11
90	Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Cardiology Clinics, 2022, 40, 301-308.	0.9	4
91	Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections. Open Forum Infectious Diseases, 2022, 9, ofac116.	0.4	15
92	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet, The, 2022, 399, 924-944.	6.3	752
93	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Science Translational Medicine, 2022, 14, eabn6150.	5.8	57
95	Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals. Vaccines, 2022, 10, 439.	2.1	7
96	Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. Journal of Infection and Chemotherapy, 2022, 28, 934-942.	0.8	9
97	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell Reports Medicine, 2022, 3, 100603.	3.3	27
98	Not only lymphadenopathy: case of chest lymphangitis assessed with MRI after COVID 19 vaccine. Infectious Agents and Cancer, 2022, 17, 8.	1.2	7
99	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet, The, 2022, 399, 1141-1153.	6.3	51
100	Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative. Journal of Clinical Oncology, 2022, 40, 1414-1427.	0.8	68
101	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. Vaccines, 2022, 10, 469.	2.1	8
102	Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. International Journal of Infectious Diseases, 2022, 119, 87-94.	1.5	35
103	Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Frontiers in Immunology, 2022, 13, 850987.	2.2	35
104	Effectiveness of COVID-19 vaccines. Journal of Infection, 2022, 84, e118-e119.	1.7	5
105	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226.	5.6	22
106	Longitudinal Aspects of VITT. Seminars in Hematology, 2022, 59, 108-114.	1.8	12

#	Article	IF	Citations
107	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ, The, 2022, 376, e069761.	3.0	393
108	Neutralizing antibody responses 300 days after SARSâ€CoVâ€2 infection and induction of high antibody titers after vaccination. European Journal of Immunology, 2022, 52, 810-815.	1.6	9
109	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. EClinicalMedicine, 2022, 45, 101326.	3.2	29
110	A Clinicianâ€™s Obligation to be Vaccinated: Four Arguments that Establish a Duty for Healthcare Professionals to be Vaccinated Against COVID-19. Journal of Bioethical Inquiry, 2022, 19, 451-465.	0.9	5
111	mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. Journal of Infectious Diseases, 2022, 226, 797-807.	1.9	25
112	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1
113	Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health, The, 2022, 7, e356-e365.	4.7	41
114	COVIDâ€19 vaccine side effects among nursing home residents and staff. Journal of Medical Virology, 2022, 94, 3491-3493.	2.5	0
116	Projecting the Pandemic Trajectory through Modeling the Transmission Dynamics of COVID-19. International Journal of Environmental Research and Public Health, 2022, 19, 4541.	1.2	2
117	SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics. Scientific Reports, 2022, 12, 5935.	1.6	17
118	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3
120	Modelling the COVID-19 epidemic and the vaccination campaign in Italy by the SUIHTER model. Infectious Disease Modelling, 2022, 7, 45-63.	1.2	11
121	Healthcare workers benefit from second dose of COVID-19 mRNA vaccine: Effects of partial and full vaccination on sick leave duration and symptoms. Public Health in Practice, 2022, 3, 100247.	0.7	6
123	Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 39-43.	0.1	2
124	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. Frontiers in Public Health, 2021, 9, 751451.	1.3	9
126	Lifeâ€changing consequences of vaccineâ€induced immuneâ€mediated thrombosis with thrombocytopenia. British Journal of Haematology, 2022, 197, 121-123.	1.2	2
128	Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 Januaryâ€“2 July 2021. Clinical Infectious Diseases, 2022, 75, e267-e275.	2.9	12
131	Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland. , 2022, 152, .		3

#	Article	IF	Citations
132	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. JAMA Network Open, 2022, 5, e227038.	2.8	23
134	Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore. Clinical Infectious Diseases, 2022, 75, 1442-1445.	2.9	53
135	Progression to Critical Illness and Death in Patients With Breakthrough Hospitalizations. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
136	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases, 2022, 9, .	0.4	62
138	COVID-19 Vaccination and Estimated Public Health Impact in California. JAMA Network Open, 2022, 5, e228526.	2.8	15
139	Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, 2022, 7, 94.	7.1	177
140	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. Molecular Biomedicine, 2022, 3, 12.	1.7	12
141	The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization. Vaccines, 2022, 10, 488.	2.1	28
142	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. Vaccines, 2022, 10, 662.	2.1	17
143	Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. Npj Vaccines, 2022, 7, 49.	2.9	7
144	Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature. Digestive Diseases and Sciences, 2022, 67, 4574-4580.	1.1	33
145	Analysis of the Effectiveness of Measures on the COVID-19 Vaccination Rate in Hong Kong. Vaccines, 2022, 10, 747.	2.1	3
146	Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 1566-1575.	0.4	12
147	SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infectious Diseases, 2022, 22, 439.	1.3	155
148	Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115720.	0.8	2
149	Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination. Interactive Cardiovascular and Thoracic Surgery, 2022, 35, .	0.5	3
150	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines, 2022, 10, 755.	2.1	13
151	The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence. JMIR Public Health and Surveillance, 2022, 8, e35054.	1.2	3

#	Article	IF	Citations
152	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. PLoS ONE, 2022, 17, e0267824.	1.1	15
153	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
154	Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infectious Diseases of Poverty, 2022, 11, 53.	1.5	25
155	The benefits of large scale covid-19 vaccination. BMJ, The, 2022, 377, o867.	3.0	21
156	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clinical Infectious Diseases, 2023, 76, e460-e468.	2.9	9
157	Public health impact of covid-19 vaccines in the US: observational study. BMJ, The, 2022, 377, e069317.	3.0	102
158	Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients > 50 Years in Korea. Journal of Korean Medical Science, 2022, 37, .	1.1	9
159	Understanding â€œHybrid Immunityâ€: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2023, 76, e439-e449.	2.9	23
162	Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 2022, 185, 2434-2451.e17.	13.5	289
163	mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	160
164	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. Clinical Rheumatology, 2022, 41, 2755-2763.	1.0	6
165	A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses, 2022, 14, 1126.	1.5	2
166	Control of COVIDâ€19 Outbreaks under Stochastic Community Dynamics, Bimodality, or Limited Vaccination. Advanced Science, 2022, 9, .	5.6	9
168	First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India. BMJ Global Health, 2022, 7, e008271.	2.0	6
169	In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology. Genes and Genomics, 2022, 44, 937-944.	0.5	3
170	Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures. Current Environmental Health Reports, 2022, 9, 477-489.	3.2	6
171	Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2022, 16, 117954842211053.	0.5	3
172	Antigenicity of genomic epidemiology concerning viral evolution and vaccine efficacy for SARS-COV-2-A review. , 2022, , .		0

#	Article	IF	Citations
173	Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021â€“November 2021. Clinical Infectious Diseases, 2023, 76, e469-e476.	2.9	9
175	The Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations During the Delta Wave: A Patient-Population Study at a Major Referral Center. Cureus, 2022, , .	0.2	0
176	Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workersâ€”Mexico, Marchâ€“December 2021. Clinical Infectious Diseases, 2022, 75, S167-S173.	2.9	7
177	Observational Study of Receptor Binding Doman Spike Antibody Responses to Three SARS-CoV-2 Vaccinations in Non-Infected Subjects: Parallel Neutralizing Antibody and Cardiac Troponin I and T Observations. journal of applied laboratory medicine, The, 0, , .	0.6	0
178	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharmâ€™s COVID-19 Vaccines. Frontiers in Immunology, 0, 13, .	2.2	33
179	Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	28
180	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Medicine, 2022, 14, .	3.6	15
181	Simplified Lung Ultrasound Examination and Telehealth Feasibility in Early SARS-CoV-2 Infection. Journal of the American Society of Echocardiography, 2022, 35, 1047-1054.	1.2	4
182	Self-Reported COVID-19 Vaccinesâ€™ Side Effects among Patients Treated with Biological Therapies in Saudi Arabia: A Multicenter Cross-Sectional Study. Vaccines, 2022, 10, 977.	2.1	0
183	The US COVID-19 surveillance environment: An ecological analysis of the relationship of testing adequacy in the context of vaccination. Clinical Infectious Diseases, 0, , .	2.9	0
185	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical Infectious Diseases, 2022, 75, S159-S166.	2.9	13
186	Increasing COVID-19 Vaccination in the United States: Projected Impact on Cases, Hospitalizations, and Deaths by Age and Racial Group. Public Health, 2022, , .	1.4	4
187	Immunological memory to <scp>SARSâ€CoV</scp>â€2 infection and <scp>COVID</scp>â€19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
188	Retrospective study on the safety of <scp>COVID</scp>â€19 vaccination in myasthenia gravis. Muscle and Nerve, 2022, 66, 558-561.	1.0	10
189	Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. Frontiers in Immunology, 0, 13, .	2.2	7
190	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
191	Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. Nature Communications, 2022, 13, .	5.8	47
192	Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies. Npj Vaccines, 2022, 7, .	2.9	23

#	Article	IF	Citations
193	Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects. Pathogens, 2022, 11, 743.	1.2	11
194	Breakthrough SARS-CoV-2 infections after COVID-19 immunization. Journal of Investigative Medicine, 2022, 70, 1429-1432.	0.7	9
195	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Reinfections Among Fully Vaccinated and Unvaccinated University Athletesâ€”15 States, Januaryâ€“November 2021. Clinical Infectious Diseases, 2022, 75, S236-S242.	2.9	4
197	Ascertainment of vaccination status by selfâ€report versus source documentation: Impact on measuring COVIDâ€19 vaccine effectiveness. Influenza and Other Respiratory Viruses, 2022, 16, 1101-1111.	1.5	15
198	Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections. Nature Communications, 2022, 13, .	5.8	10
199	SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge â€“ Denver, Colorado, and San Diego, California, Januaryâ€“April 2021. Vaccine, 2022, 40, 4845-4855.	1.7	2
200	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	4.2	10
201	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. Scientific Reports, 2022, 12, .	1.6	4
202	Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults. Nature Communications, 2022, 13, .	5.8	18
203	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. Vaccines, 2022, 10, 1103.	2.1	11
204	Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France. Lancet Regional Health - Europe, The, 2022, 19, 100441.	3.0	13
205	COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD. Multiple Sclerosis and Related Disorders, 2022, 65, 104003.	0.9	7
206	COVIDâ€19 vaccine effectiveness against hospitalization due to SARSâ€CoVâ€2: A testâ€negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain. Influenza and Other Respiratory Viruses, 2022, 16, 1014-1025.	1.5	3
208	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections occurring in healthcare workers after booster vaccination: A comparison of delta versus omicron variants. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
209	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. Npj Vaccines, 2022, 7, .	2.9	13
211	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Frontiers in Public Health, 0, 10, .	1.3	70
212	Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors. Journal of Infectious Diseases, 2022, 226, 1556-1561.	1.9	3
213	Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination. Vaccines, 2022, 10, 1363.	2.1	5

#	Article	IF	Citations
215	Geographic, Occupational, and Sociodemographic Variations in Uptake of COVID-19 Booster Doses Among Fully Vaccinated US Adults, December 1, 2021, to January 10, 2022. JAMA Network Open, 2022, 5, e2227680.	2.8	15
216	Surge in Incidence and COVID-19 Hospital Risk of Death, United States, September 2020 to March 2021. Open Forum Infectious Diseases, 0, , .	0.4	2
217	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	4.2	12
218	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. Scientific Reports, 2022, 12, .	1.6	2
219	The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. Current Opinion in Immunology, 2022, 78, 102234.	2.4	4
220	Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. Virus Research, 2022, 319, 198882.	1.1	10
221	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. International Journal of Infectious Diseases, 2022, 123, 183-191.	1.5	8
222	Modular nanoarray vaccine for SARS-CoV-2. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 46, 102604.	1.7	2
223	Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Mathematical Biosciences and Engineering, 2022, 20, 179-212.	1.0	6
224	Geographic Patterns of COVID-19 Vaccination, Infection, and Mortality in the United States During YearÂTwo of the Pandemic and the Influence of Political Orientation. , 2022, , 341-355.		0
225	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	2
226	Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal of Occupational and Environmental Medicine, 2022, 64, 788-796.	0.9	0
227	A Review of Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination Following Solid Organ Transplantation. Annals of Transplantation, 0, 27, .	0.5	0
228	Hybrid and vaccineâ€induced immunity against <scp>SARâ€CoV</scp>â€2 in <scp>MS</scp> patients on different diseaseâ€modifying therapies. Annals of Clinical and Translational Neurology, 2022, 9, 1643-1659.	1.7	9
229	COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variantâ€"Zambia, December 2021. American Journal of Tropical Medicine and Hygiene, 2022, 107, 1055-1059.	0.6	3
230	Durability of Protection Postâ€"Primary COVID-19 Vaccination in the United States. Vaccines, 2022, 10, 1458.	2.1	8
231	Immunogenicity of two doses of <scp>BNT162b2</scp> and <scp>mRNA</scp>â€1273 vaccines for solid cancer patients on treatment with or without a previous <scp>SARSâ€CoV</scp>â€2 infection. International Journal of Cancer, 2023, 152, 661-671.	2.3	3
232	The correlation between COVIDâ€19 vaccination and cardiac surgery: When is safe to vaccinate?. Journal of Cardiac Surgery, 2022, 37, 3639-3641.	0.3	2

#	Article	IF	Citations
233	Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers. Biomedicines, 2022, 10, 2402.	1.4	2
234	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. Npj Vaccines, 2022, 7, .	2.9	3
235	Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients. Tomography, 2022, 8, 2403-2410.	0.8	0
236	Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan. Frontiers in Public Health, 0, 10, .	1.3	7
237	Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. Applied Mathematical Modelling, 2023, 114, 447-465.	2.2	23
238	COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS). BMC Women's Health, 2022, 22, .	0.8	17
239	Third wave COVID-19 delta variant breakthrough infection in a Hispanic-dominant suburb of Miami, Florida: ethical dilemma and vaccination hesitancy. , 2022, 10, 251513552211280.	1.4	2
240	Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211336.	1.0	2
241	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
242	SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021. Acta Medica Portuguesa, 2023, 36, 5-14.	0.2	2
243	Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method. Vaccines, 2022, 10, 1824.	2.1	6
244	Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Frontiers in Immunology, 0, 13, .	2.2	8
245	Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ, The, 0, , e072065.	3.0	54
246	Comparative analysis of mRNA and inactivated COVID-19 vaccines: A study from Faisalabad district of Pakistan. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 240-246.	0.2	2
247	Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222. Vaccines, 2022, 10, 1701.	2.1	3
248	Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Frontiers in Immunology, 0, 13, .	2.2	15
249	Long COVID-19 and Health-Related Quality of Life of Mild Cases in Korea: 3-Months Follow-up of a Single Community Treatment Center. Journal of Korean Medical Science, 2022, 37, .	1.1	5
250	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. BMC Infectious Diseases, 2022, 22, .	1.3	5

#	Article	IF	Citations
251	Combining predictive models with future change scenarios can produce credible forecasts of COVID-19 futures. PLoS ONE, 2022, 17, e0277521.	1.1	3
252	The Long-COVID Experience Changed Peopleâ€™s Vaccine Hesitancy but Not Their Vaccination Fear. International Journal of Environmental Research and Public Health, 2022, 19, 14550.	1.2	8
253	The â€œvaccineâ€•hubbub: Viral load comparisons of SARSâ€CoVâ€2 Delta and Omicron variants against different vaccineâ€“booster vaccine combinations. Journal of Medical Virology, 2023, 95, .	2.5	0
254	Why some people do not get vaccinated against COVIDâ€19: Socialâ€cognitive determinants of vaccination behavior. Applied Psychology: Health and Well-Being, 2023, 15, 825-845.	1.6	4
256	Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster. Cancers, 2022, 14, 5537.	1.7	1
257	Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs. Vaccines, 2022, 10, 2044.	2.1	2
258	Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers. PLoS ONE, 2022, 17, e0277827.	1.1	7
259	Considerations and Challenges for Real-World Deployment of an Acoustic-Based COVID-19 Screening System. Sensors, 2022, 22, 9530.	2.1	2
261	Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. Vaccine, 2023, 41, 989-998.	1.7	1
262	Cardiorespiratory fitness and depression symptoms among adults during the COVID-19 Pandemic: Cooper Center Longitudinal Study. Preventive Medicine Reports, 2022, 30, 102065.	0.8	2
263	COVID-19 Vaccines, Effectiveness, and Immune Responses. International Journal of Molecular Sciences, 2022, 23, 15415.	1.8	9
264	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Scientific Reports, 2022, 12, .	1.6	20
265	Navigating Coronavirus Disease 2019 Vaccination and Uveitis. Ophthalmology, 2023, 130, 501-508.	2.5	5
266	An Optimization of COVID-19 Vaccine Distribution in Canada Based on the VRP Model. Journal of Physics: Conference Series, 2022, 2381, 012114.	0.3	1
267	Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out. Expert Opinion on Drug Delivery, 2023, 20, 175-187.	2.4	2
268	Immune Response to Vaccination against COVID-19 at Different Second-Dose Intervals and Their Associations with Metabolic Parameters. Vaccines, 2023, 11, 149.	2.1	1
269	Humoral immunity for durable control of SARS-CoV-2 and its variants. Inflammation and Regeneration, 2023, 43, .	1.5	6
270	A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20, 5379-5412.	1.0	4

#	Article	IF	Citations
271	Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. JHEP Reports, 2023, 5, 100697.	2.6	7
272	COVID-19 pandemic in prisons in Spain: characteristics of cases and implemented control measures, March 2020â€"June 2022. Public Health, 2023, 218, 45-52.	1.4	1
273	A population-based paediatric Covid-19 vaccination progress and outcomes: The Malta case. Ethics, Medicine and Public Health, 2023, 28, 100901.	0.5	0
274	Assessing parameter sensitivity in a university campus COVID-19 model with vaccinations. Infectious Disease Modelling, 2023, 8, 374-389.	1.2	0
275	Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. American Journal of Epidemiology, 2023, 192, 895-907.	1.6	6
276	Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study. Vaccines, 2023, 11, 297.	2.1	0
277	Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. Journal of Nutrition, Health and Aging, 2023, 27, 81-88.	1.5	4
278	A SARS-CoV-2 outbreak associated with five air force bases and a nightclub following the lifting of COVID-19-related social restrictions, United Kingdom, July-to-September 2021. Epidemiology and Infection, 2023, 151, .	1.0	0
279	Advances in Research on COVID-19 Vaccination for People Living with HIV. Infectious Diseases & Immunity, 2022, 2, 213-218.	0.2	5
280	Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. International Journal of Infectious Diseases, 2023, 129, 188-196.	1.5	10
282	Serological response to vaccination in post-acute sequelae of COVID. BMC Infectious Diseases, 2023, 23, .	1.3	6
283	Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines. Circulation, 2023, 147, 877-880.	1.6	8
284	ï»¿Comparison of the efficacy of one, two, and third doses of BNT162b2 in patients suffering from cardiovascular diseases, respiratory diseases, and diabetes against COVID-19. Pharmacia, 2023, 70, 155-159.	0.4	2
285	Reporting rates for <scp>VAERS</scp> death reports following <scp>COVID</scp> â€19 vaccination, December 14, 2020â€"November 17, 2021. Pharmacoepidemiology and Drug Safety, 0, , .	0.9	0
286	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. Frontiers in Immunology, 0, 14, .	2.2	4
287	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50Âyears and over in France. Vaccine, 2023, 41, 2280-2288.	1.7	5
288	Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Heart Failure Clinics, 2023, 19, 177-184.	1.0	0
289	The Coming of Age of Nucleic Acid Vaccines during COVID-19. MSystems, 2023, 8, .	1.7	5

#	Article	IF	Citations
290	Respiratory syncytial virus with ongoing COVID-19: is it an emerging threat?. Annals of Medicine and Surgery, 2023, 85, 67-70.	0.5	7
291	Effectiveness of mRNA and viralâ€vector vaccines in epidemic period led by different SARSâ€CoVâ€2 variants: A systematic review and metaâ€analysis. Journal of Medical Virology, 2023, 95, .	2.5	3
292	COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. The Lancet Regional Health Americas, 2023, 20, 100461.	1.5	8
293	Loss of antiâ€spike antibodies following <scp>mRNA</scp> vaccination for <scp>COVID</scp> â€19 among patients with multiple myeloma. Cancer Reports, 0, , .	0.6	2
294	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
295	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. IScience, 2023, 26, 106457.	1.9	3
296	Analysis of application of covid-19 vaccine in Mexico city by age and gender groups in the second wave of the pandemic. International Journal of Vaccines & Vaccination, 2022, 7, 3-7.	0.3	0
297	Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. Journal of the American Medical Directors Association, 2023, 24, 753-758.	1.2	6
298	Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations. Multiple Sclerosis Journal, 2023, 29, 884-888.	1.4	2
299	Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. Frontiers in Immunology, 0, 14, .	2.2	0
300	COVID-19 in Children and Adolescents. , 2024, , 253-266.		0
301	A novel Rift Valley fever vaccine. Lancet Infectious Diseases, The, 2023, , .	4.6	0
315	Overview of the cardio-metabolic impact of the COVID-19 pandemic. Endocrine, 2023, 80, 477-490.	1.1	1
337	Comparative Analysis of IgG Antibody Titers Induced by Three Different SARS-COV-2 Vaccines in Healthy Adults of Pakistan. Current Microbiology, 2023, 80, .	1.0	0